Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 5Carboplatin 5Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4pembrolizumab 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Gemcitabine 3Fluorouracil 3Docetaxel 3Capecitabine 3tislelizumab 2fludarabine 2Specimen Handling 2Riluzole 2Quality of Life 2Psychiatric Rehabilitation 2Oncolytic Virotherapy 2Observation 2Fluorodeoxyglucose F18 2Fluorescein 2Floxuridine 2Filgrastim 2Drug Therapy 2Cetuximab 2umbralisib 1trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Medicare Part B × Sarcoma × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡